Mannkind (MNKD) Net Income towards Common Stockholders (2010 - 2026)
Mannkind's (MNKD) quarterly Net Income towards Common Stockholders came in at -$16.6 million in Q1 2026, down 226.3% year-on-year from $13.2 million in Q1 2025, and down 4.21% on a QoQ basis from -$15.9 million in Q4 2025.
Mannkind (MNKD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$16.6 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 226.3% year-over-year to -$16.6 million in Q1 2026; TTM through Mar 2026 was -$23.9 million, a 179.53% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, down 78.75% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$16.6 million, down from -$15.9 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for MNKD reached as high as $13.2 million in Q1 2025 and fell as low as -$29.0 million in Q2 2022.
- Historically, Net Income towards Common Stockholders has averaged -$4.7 million across 5 years, with a median of -$2.0 million in 2024.
- Across the five-year window, Net Income towards Common Stockholders jumped 427.01% in 2024 and sank 315.08% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$17.9 million in 2022, then jumped by 107.84% to $1.4 million in 2023, then soared by 427.01% to $7.4 million in 2024, then sank by 315.08% to -$15.9 million in 2025, then fell by 4.21% to -$16.6 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$16.6 million in Q1 2026, -$15.9 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | -453.82 Mn |
| 10 | Mannkind | 1.25 Bn | 1.12 Bn | 82.66 Mn | -16.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.62 Mn |
| Dec 31, 2025 | -15.95 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 640,000.00 |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | 11.55 Mn |
| Jun 30, 2024 | -2.01 Mn |
| Mar 31, 2024 | 10.63 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.43 Mn |
| Jun 30, 2022 | -29.02 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -28.06 Mn |
| Sep 30, 2021 | -4.43 Mn |
| Jun 30, 2021 | -35.52 Mn |